Matrixyl 3000

Palmitoyl tripeptide-1 is a lipidated GHK that acts as a matrikine on fibroblasts, raising collagen I, collagen IV, fibronectin and hyaluronic acid output. Palmitoyl tetrapeptide-7 is a lipidated GQPR fragment derived from immunoglobulin G that reduces IL-6 release from stimulated fibroblasts and keratinocytes, which in turn lowers MMP-driven matrix breakdown and the glycation-related damage that accompanies chronic low-grade inflammation. The commercial logic is build-plus-protect rather than a single pathway. Neither component has a cleanly mapped receptor; both are characterised by their downstream gene and protein output.

Targets: Dermal fibroblasts, Collagen I and IV, Hyaluronic acid, Interleukin-6, Glycosaminoglycan synthesis

• · Supplied as a dilute trade solution, used at 3-8% of the finished formula. That corresponds to roughly 30-100 ppm of each actual peptide. Products advertising '10% Matrixyl 3000' are quoting the trade solution.

Work out your exact syringe units →

• rareIrritation— Very well tolerated at cosmetic use levels.

• redundantmatrixyl — Same matrikine strategy; running both at full strength is spending twice for one effect.
• redundantpalmitoyl-tripeptide-1 — Palmitoyl tripeptide-1 is literally half of this blend.
• synergyargireline — Structural collagen building plus expression-line softening; different problems, commonly combined.

• · Standardised photography at 0, 8 and 16 weeks.

Cosmetic ingredient blend approved worldwide under its component INCI names.

• Sederma Matrixyl 3000 technical dossier (other)

The commercial pitch is build-plus-protect and, unusually for this category, that framing is mechanistically defensible even though the clinical data are not. Palmitoyl tripeptide-1 is lipidated GHK acting as a matrikine — collagen I, collagen IV, fibronectin, hyaluronic acid and glycosaminoglycan output up, through the same undefined route as the rest of the matrikine family. Palmitoyl tetrapeptide-7 does something genuinely different: it reduces IL-6 release from stimulated fibroblasts and keratinocytes. IL-6 matters here because it is the cytokine that sits at the junction between chronic low-grade inflammation and matrix destruction. IL-6 drives MMP-1 and MMP-3 transcription, and MMP-1 is the interstitial collagenase that does the actual cutting in photoaged dermis. So suppressing IL-6 is an upstream way of reducing collagen breakdown without touching the MMPs directly. Combining a synthesis signal with an inflammation-driven-degradation brake is a coherent strategy, and it is a better-reasoned product than most in this class. The problem is entirely on the evidence side. The wrinkle-volume numbers everyone quotes — typically framed as around 45% reduction in wrinkle volume and 16% in wrinkle depth over two months — come from Sederma's own uncontrolled in-vivo panels. Uncontrolled means no vehicle arm, which for a moisturising base applied twice daily for eight weeks is a serious omission, because the vehicle alone moves those endpoints.

Almost everyone misreads the concentration. Matrixyl 3000 is a dilute trade solution and the supplier use level is 3-8% of the finished formula, which puts the actual peptides at roughly 30-100 ppm each. A product advertising '10% Matrixyl 3000' contains about 0.01% peptide, and a DIY maker who tries to hit 10% actual peptide from raw components has made something a thousand times stronger than any tested formulation. The second problem is buying it for the wrong indication. This is a slow structural active for photoaged skin. It does nothing for expression lines, nothing for pigment, nothing for pores, and nothing quickly. Third, judging it at four weeks. The manufacturer's own panels ran eight weeks; the realistic assessment window is twelve to sixteen.

• Unidentified fibroblast matrikine receptor (palmitoyl tripeptide-1 arm) — No receptor cloned, no Kd published

  Increased collagen I, collagen IV, fibronectin, hyaluronic acid and glycosaminoglycan synthesis.

• Interleukin-6 release from fibroblasts and keratinocytes (palmitoyl tetrapeptide-7 arm) — Not published as a binding affinity; described as reduced IL-6 secretion in stimulated cell culture

  Lowers IL-6-driven MMP-1 and MMP-3 transcription, which is the practical route by which chronic inflammation degrades dermal collagen.

Week 0-4: nothing you can see. Week 8: the earliest point manufacturer panels report wrinkle-volume change, and roughly when photographs start to differ. Week 12-16: realistic assessment point. Plateau thereafter. Because the IL-6 arm is a brake on degradation rather than a synthesis signal, some of the benefit is preventing future loss, which by definition never looks like anything.

Chemically inert and compatible with essentially everything, including vitamin C, acids and retinoids — the palmitoyl tripeptide-1 in it carries no copper, so none of the GHK-Cu incompatibilities apply. The pairing Sederma itself promotes is Matrixyl 3000 with Matrixyl Synthe'6, positioned as dermis plus dermal-epidermal junction. That is a marketing construct with no comparative data behind it, but it is at least not contradictory. Do not run Matrixyl 3000 alongside standalone palmitoyl tripeptide-1 or Haloxyl, because palmitoyl tripeptide-1 is already in both. The genuinely additive partners are a retinoid, GHK-Cu at a different time of day, and niacinamide, which independently reduces inflammatory signalling and hits the same IL-6 axis from another direction.

Better-reasoned than plain Matrixyl, worse-evidenced. Plain Matrixyl has a 93-subject double-blind vehicle-controlled facial trial; Matrixyl 3000 has uncontrolled supplier panels. If you weight evidence, buy plain Matrixyl. If you weight mechanism, the IL-6 arm is a genuine addition that plain Matrixyl lacks. Against GHK-Cu, this is the copper-free alternative that layers with vitamin C, at the cost of losing all the copper-dependent enzyme effects. Against a retinoid, no contest, as usual.

$10–$70/month. The trade solution runs roughly $20-40 per 100 mL at ingredient suppliers, which at 5% use level makes two litres of finished serum. Retail products containing it range from about $10 to $70 a month. Market observation, not a sourced pricing study.

• ?No independent randomised trial of the blend exists. Every efficacy number in circulation is from Sederma.
• ?The IL-6 suppression data for palmitoyl tetrapeptide-7 come from supplier cell-culture work that I could not resolve to a primary indexed publication in this session.
• ?The GQPR-from-immunoglobulin-G derivation is repeated in every marketing document but I could not verify it against a primary source.
• ?The relative contribution of the two components is unknown because they have never been tested separately in humans.
• ?No molecular weight is given in the Core record because it is a blend; the individual components are approximately 579 Da and 807 Da, but I could not confirm the tetrapeptide-7 figure from a primary source.

• A pentapeptide from type I procollagen promotes extracellular matrix production Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM, Journal of Biological Chemistry, 1993 · PMID 8486721

  Background on the matrikine concept that both components of this blend rely on.

• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data Pickart L, Margolina A, International Journal of Molecular Sciences, 2018 · PMID 29986520

  Background on the GHK backbone, which is what palmitoyl tripeptide-1 becomes once the lipid is cleaved.

• Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM, Frontiers in Chemistry, 2020 · PMID 33195061

  Independent survey placing the Matrixyl family in context against the rest of the field.

• Overview of popular cosmeceuticals in dermatology Crous C, Pretorius J, Petzer A, Skin Health and Disease, 2024 · PMID 38577050

  A dermatology-side review of what is actually in these products and how good the evidence is.

• A framework for the safety evaluation of peptides in cosmetics Bjerke DL, Li J, Gao Y, Hu P, Lintner K, Hakozaki T, Current Research in Toxicology, 2026 · PMID 41953401

  Co-authored by Karl Lintner, who developed Matrixyl. Useful for how the industry itself reasons about peptide safety and exposure.